Storage: Lyophilized refrigerated 28 C
In C57BL/6J mice, oral treatment with EGCG (200 mg/kg for 3 or 12 h) caused both induction and suppression of expression of numerous genes in the liver and small intestine, importantly Nrf2-regulated phase II genes such as heme oxygenase 1 and alcohol dehydrogenase were induced [97]
According to the financial reports by Novo Nordisk, the business revenue of GLP-1 RAs has reached 34,653 million Danish krone (DKK) in the first quarter of 2023 ( The FDA Adverse Event Reporting System (FAERS) is a robust pharmacovigilance database that contains real-world data on AE reporting ( Methods Data sources FAERS is an openly accessible pharmacovigilance database documenting AEs, medication errors, and product quality complaints reported spontaneously by people of diverse occupations worldwide ( Data extraction In order to acquire AE reports data treated with GLP-1 RAs, we identified the AEs of GLP-1 RAs in the DRUG files using the generic and brand names of the FDA-approved GLP-1 RAs, specifically exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), lixisenatide (ADLYXIN, SOLIQUA), dulaglutide (TRULICITY), semaglutide (OZEMPIC, RYBELSUS, WEGOVY), and tirzepatide (MOUNJARO)
doi: 10.3390/nu12082282
Symptoms of deficiency include fatigue, numbness or tingling in hands and feet, cognitive fog, and anemia
